EUVIMEDEUVIMED entdecken
Crossref

CALLY index as an independent predictor of pathological complete response in HER2-positive breast cancer receiving neoadjuvant therapy

Salih Karatlı, Özgen Ahmet Yıldırım

Clinical and Translational Oncology · 2025

DOI: 10.1007/s12094-025-04077-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Oncology, 2025. Verfasst von Salih Karatlı und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Etlik City Hospital, Ankara, Turkey. karatlisalih@hotmail.com. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) is a validated endpoint for long-term survival in HER2-positive breast cancer. Identifying clinical and biomarker-based predictors of pCR is essential for optimizing treatment strategies. This study investigated the predictive role of nutrition- and inflammation-based indices (HALP, CALLY, PNI, SII, PIV, SIRI, NLR) in determining pCR. METHODS: A total of 169 HER2-positive patients who underwent NACT followed by surgery at Ankara Etlik City Hospital between January 2023 and December 2024 were retrospectively analyzed. Indices were calculated from baseline laboratory values. Receiver operating characteristic (ROC) analysis was used to evaluate discriminatory ability and determine cut-off values for significant variables. Univariate logistic regression was performed initially; variables significant at the univariate level were included in the multivariate model. RESULTS: The overall pCR rate was 56.8%. ROC analysis identified the CALLY index (AUC = 0.681; p < 0.001) and Ki-67 (AUC = 0.603; p = 0.022) as significant predictors, while HALP, PNI, NLR, PIV, SII, and SIRI lacked predictive value. In univariate analysis, high CALLY (p < 0.001), high Ki-67 (p = 0.012), and pertuzumab-containing regimens [AC + taxane + trastuzumab + pertuzumab (p = 0.003) and docetaxel + trastuzumab + carboplatin + pertuzumab (THCP) (p = 0.004)] were associated with higher pCR, whereas ER positivity was associated with a reduced likelihood of pCR (OR = 0.41; p = 0.011). In multivariate analysis, CALLY (OR = 4.03; p < 0.001), Ki-67 (OR = 2.21; p = 0.038), and pertuzumab-containing regimens remained independent predictors: AC + taxane + trastuzumab + pertuzumab (OR = 3.24; p = 0.020) and THCP (OR = 3.86; p = 0.037). Although ER positivity was significant in univariate analysis, it lost statistical significance in the multivariate model (OR = 0.49; p = 0.072). CONCLUSIONS: High CALLY index and high Ki-67 were found to be statistically significant in predicting pCR, and pertuzumab-containing regimens were shown to increase pCR rates. In contrast, classical histopathological parameters and other immunonutritional scores demonstrated limited predictive value. These findings require validation through prospective, multicenter studies. The limited number of studies investigating the association between pCR and CALLY highlights the originality of our work.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMiddle AgedRetrospective StudiesAdultBiomarkers, TumorAgedROC CurveChemotherapy, AdjuvantTrastuzumabDocetaxelPrognosisKi-67 AntigenTaxoidsAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

CALLY indexHER2-positive breast cancerNACTPCR

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, humanBiomarkers, TumorTrastuzumabDocetaxelpertuzumabKi-67 AntigenTaxoidsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Medical Oncology, Etlik City Hospital, Ankara, Turkey. karatlisalih@hotmail.com.
  • Department of Medical Oncology, Etlik City Hospital, Ankara, Turkey.

Zitieren

APA

Karatlı, S., & Yıldırım, Ö. A. (2025). CALLY index as an independent predictor of pathological complete response in HER2-positive breast cancer receiving neoadjuvant therapy. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-025-04077-8

Vancouver

Karatlı S, Yıldırım ÖA. CALLY index as an independent predictor of pathological complete response in HER2-positive breast cancer receiving neoadjuvant therapy. Clinical and Translational Oncology. 2025. doi:10.1007/s12094-025-04077-8

BibTeX
@article{Karatl2025,
  author = {Karatlı, Salih and Yıldırım, Özgen Ahmet},
  title = {CALLY index as an independent predictor of pathological complete response in HER2-positive breast cancer receiving neoadjuvant therapy},
  journal = {Clinical and Translational Oncology},
  year = {2025},
  doi = {10.1007/s12094-025-04077-8}
}
Kostenlos starten →